Central govt officials team in continuous dialogue with Pfizer, Moderna, JnJ on indemnity, other issues, Says Minister

Published On 2021-07-24 11:42 GMT   |   Update On 2021-07-24 11:42 GMT

New Delhi: A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues, including indemnity, the Lok Sabha was informed on Friday.Providing the present status of discussions with pharma companies like Pfizer and Moderna over giving them indemnity against cost...

Login or Register to read the full article

New Delhi: A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues, including indemnity, the Lok Sabha was informed on Friday.

Providing the present status of discussions with pharma companies like Pfizer and Moderna over giving them indemnity against cost of compensation for adverse effects due to vaccination, Union Minister Bharati Pravin Pawar in a written reply said the government constituted the team on June 11 to deal with various issues related to procurement of COVID-19 vaccine from foreign manufacturers.

Read also: Covid-19: JnJ, Pfizer yet to apply for license of vaccines in India

"This team is in continuous dialogue with Pfizer, Moderna and Johnson and Johnson to discuss and address various issues including the issue of indemnity," the minister of state for health said.

She clarified that no domestic manufacturer of Covid vaccine has demanded indemnity against adverse effects of vaccination.

Read also: Covid-19: JnJ, Pfizer yet to apply for license of vaccines in India



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News